Christopher Burns is the founder of Venatorx Pharmaceuticals, Inc.. Venatorx Pharmaceuticals, Inc. has raised $46M in total funding. Latest round: Series B.
Christopher Burns is the CEO of Venatorx Pharmaceuticals, Inc., a company focused on antibiotic research and development, particularly for multidrug-resistant Gram-negative infections. The company aims to advance its lead treatment, VNRX-5133, through clinical trials for FDA approval. Prior to Venatorx, Burns, along with co-founders Luigi Xerri and Daniel Pevear, worked at Protez Pharmaceuticals, which was acquired by Novartis for $400 million.
Full founder directory · Investor directory · Company funding database · Fundraising library